Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander Egle

Showing results (81-90 of 107) with videos related to

Pageof 11
Sort By:
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 24, 2021
Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathyStefan Hatzl, Florian Posch, Arwin Rezai, et al.
Journal of Hematology & Oncology|May 1, 2013
Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study GroupLisa Pleyer, Reinhard Stauder, Sonja Burgstaller, et al.
Wiener Klinische Wochenschrift|February 1, 2018
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemiaFlorian Huemer, Lukas Weiss, Viktoria Faber, et al.
International Journal of Environmental Research and Public Health|December 10, 2021
A Lower CD4 Count Predicts Most Causes of Death except Cardiovascular Deaths. The Austrian HIV Cohort StudyGisela Leierer, Armin Rieger, Brigitte Schmied, et al.
Blood|August 12, 2015
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia veraHeinz Gisslinger, Oleh Zagrijtschuk, Veronika Buxhofer-Ausch, et al.
Blood|January 11, 2018
Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemiaPavlina Janovska, Jan Verner, Jiri Kohoutek, et al.
ESC Heart Failure|December 22, 2020
Myocardial injury in severe COVID-19 is similar to pneumonias of other origin: results from a multicentre studyPeter Jirak, Robert Larbig, Zornitsa Shomanova, et al.
Science Translational Medicine|January 17, 2020
Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistanceEugene Park, Jingyu Chen, Andrew Moore, et al.
Cancers|March 11, 2023
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMTLisa Pleyer, Sonja Heibl, Christoph Tinchon, et al.
Leukemia & Lymphoma|September 27, 2019
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general populationHeinz Ludwig, Wolfram Pönisch, Stefan Knop, et al.
Pageof 11

Showing results (81-90 of 107) with videos related to

Sort By:
Pageof 11
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 24, 2021
Vinorelbine as substitute for vincristine in patients with diffuse large B cell lymphoma and vincristine-induced neuropathyStefan Hatzl, Florian Posch, Arwin Rezai, et al.
Journal of Hematology & Oncology|May 1, 2013
Azacitidine in patients with WHO-defined AML - results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study GroupLisa Pleyer, Reinhard Stauder, Sonja Burgstaller, et al.
Wiener Klinische Wochenschrift|February 1, 2018
Establishment and validation of a novel risk model for estimating time to first treatment in 120 patients with chronic myelomonocytic leukaemiaFlorian Huemer, Lukas Weiss, Viktoria Faber, et al.
International Journal of Environmental Research and Public Health|December 10, 2021
A Lower CD4 Count Predicts Most Causes of Death except Cardiovascular Deaths. The Austrian HIV Cohort StudyGisela Leierer, Armin Rieger, Brigitte Schmied, et al.
Blood|August 12, 2015
Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia veraHeinz Gisslinger, Oleh Zagrijtschuk, Veronika Buxhofer-Ausch, et al.
Blood|January 11, 2018
Casein kinase 1 is a therapeutic target in chronic lymphocytic leukemiaPavlina Janovska, Jan Verner, Jiri Kohoutek, et al.
ESC Heart Failure|December 22, 2020
Myocardial injury in severe COVID-19 is similar to pneumonias of other origin: results from a multicentre studyPeter Jirak, Robert Larbig, Zornitsa Shomanova, et al.
Science Translational Medicine|January 17, 2020
Stromal cell protein kinase C-β inhibition enhances chemosensitivity in B cell malignancies and overcomes drug resistanceEugene Park, Jingyu Chen, Andrew Moore, et al.
Cancers|March 11, 2023
Health-Related Quality of Life as Assessed by the EQ-5D-5L Predicts Outcomes of Patients Treated with Azacitidine-A Prospective Cohort Study by the AGMTLisa Pleyer, Sonja Heibl, Christoph Tinchon, et al.
Leukemia & Lymphoma|September 27, 2019
Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general populationHeinz Ludwig, Wolfram Pönisch, Stefan Knop, et al.
Pageof 11